Tags

Type your tag names separated by a space and hit enter

Risk and benefits of continuous subcutaneous insulin infusion (CSII) treatment in school children and adolescents.
Pediatr Diabetes. 2006 Aug; 7 Suppl 4:20-4.PD

Abstract

Continuous subcutaneous insulin infusion (CSII) therapy with technically advanced modern insulin pumps is a treatment option enabling patients and multidisciplinary diabetes teams to achieve all current goals for the treatment of children and adolescents with type 1 diabetes mellitus (T1DM): near-normoglycemia, low rate of hypoglycemia, preventing or delaying long-term complications and increasing quality of life. Clinical studies demonstrate that CSII therapy reduces glycosylated hemoglobin A1c (HbA1c) with a concomitant decrease in the rate of hypoglycemic events, without excessive weight gain and with an increase of patients' treatment satisfaction in all pediatric age groups. With the development of continuous glucose sensing coupled with an insulin pump, patients can hope for an ever-increasing technological support for the management of insulin therapy in the foreseeable future.

Authors+Show Affiliations

Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children's Hospital, Ljubljana, Slovenia. tadej.battelino@mf.uni-lj.si

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16774614

Citation

Battelino, Tadej. "Risk and Benefits of Continuous Subcutaneous Insulin Infusion (CSII) Treatment in School Children and Adolescents." Pediatric Diabetes, vol. 7 Suppl 4, 2006, pp. 20-4.
Battelino T. Risk and benefits of continuous subcutaneous insulin infusion (CSII) treatment in school children and adolescents. Pediatr Diabetes. 2006;7 Suppl 4:20-4.
Battelino, T. (2006). Risk and benefits of continuous subcutaneous insulin infusion (CSII) treatment in school children and adolescents. Pediatric Diabetes, 7 Suppl 4, 20-4.
Battelino T. Risk and Benefits of Continuous Subcutaneous Insulin Infusion (CSII) Treatment in School Children and Adolescents. Pediatr Diabetes. 2006;7 Suppl 4:20-4. PubMed PMID: 16774614.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk and benefits of continuous subcutaneous insulin infusion (CSII) treatment in school children and adolescents. A1 - Battelino,Tadej, PY - 2006/6/16/pubmed PY - 2006/12/9/medline PY - 2006/6/16/entrez SP - 20 EP - 4 JF - Pediatric diabetes JO - Pediatr Diabetes VL - 7 Suppl 4 N2 - Continuous subcutaneous insulin infusion (CSII) therapy with technically advanced modern insulin pumps is a treatment option enabling patients and multidisciplinary diabetes teams to achieve all current goals for the treatment of children and adolescents with type 1 diabetes mellitus (T1DM): near-normoglycemia, low rate of hypoglycemia, preventing or delaying long-term complications and increasing quality of life. Clinical studies demonstrate that CSII therapy reduces glycosylated hemoglobin A1c (HbA1c) with a concomitant decrease in the rate of hypoglycemic events, without excessive weight gain and with an increase of patients' treatment satisfaction in all pediatric age groups. With the development of continuous glucose sensing coupled with an insulin pump, patients can hope for an ever-increasing technological support for the management of insulin therapy in the foreseeable future. SN - 1399-543X UR - https://www.unboundmedicine.com/medline/citation/16774614/Risk_and_benefits_of_continuous_subcutaneous_insulin_infusion__CSII__treatment_in_school_children_and_adolescents_ L2 - https://doi.org/10.1111/j.1399-543X.2006.00167.x DB - PRIME DP - Unbound Medicine ER -